Company profile
VIVUS
Specialty pharma -- wholly-owned subsidiary of Icahn Enterprises (via IEH Biopharma LLC) since its Chapter 11 emergence; formerly NASDAQ-listed as VVUS
Privately held: no public share price · USA
Assets
(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
phentermine/topiramate(Qsymia) | Approved | Noradrenergic/anticonvulsant (combination)Small molecule | Obesity |
| Phase 3 | CalcineurinSmall molecule | Indication not yet linked |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.